Chronic Use of Statins and Their Effect on Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis by Mahamid, M et al.
ORIGINAL RESEARCH
published: 29 June 2018
doi: 10.3389/fphar.2018.00704
Frontiers in Pharmacology | www.frontiersin.org 1 June 2018 | Volume 9 | Article 704
Edited by:
Jean-Paul Deslypere,
Besins Healthcare, Thailand
Reviewed by:
Joao Massud,
Trials Consulting, Brazil
Domenico Criscuolo,
Genovax S.r.l., Italy
*Correspondence:
Abdulla Watad
watad.abdulla@gmail.com
†These authors have contributed
equally to this work.
Specialty section:
This article was submitted to
Pharmaceutical Medicine and
Outcomes Research,
a section of the journal
Frontiers in Pharmacology
Received: 20 February 2018
Accepted: 11 June 2018
Published: 29 June 2018
Citation:
Mahamid M, Watad A, Bragazzi NL,
Wengrower D, Wolff J, Livovsky D,
Amital H, Adawi M and Goldin E
(2018) Chronic Use of Statins and
Their Effect on Prevention of
Post-Endoscopic Retrograde
Cholangiopancreatography
Pancreatitis. Front. Pharmacol. 9:704.
doi: 10.3389/fphar.2018.00704
Chronic Use of Statins and Their
Effect on Prevention of
Post-Endoscopic Retrograde
Cholangiopancreatography
Pancreatitis
Mahmud Mahamid 1,2†, Abdulla Watad 3,4*†, Nicola L. Bragazzi 5, Dov Wengrower 1,
Julie Wolff 6, Dan Livovsky 1, Howard Amital 3,4, Mohammad Adawi 7† and Eran Goldin 1†
1Disgestive Diseases Institute, Sharee Zedek Medical Center, Jerusalem, Israel, 2 Endoscopy Unit, Faculty of Medicine,
Nazareth Hospital EMMS, Bar-Ilan University, Safed, Israel, 3Department of Medicine ’B’, The Zabludowicz Center for
Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel, 4 Sackler Faculty of Medicine, Tel-Aviv University,
Tel-Aviv, Israel, 5Department of Health Sciences, School of Public Health, University of Genoa, Genoa, Italy, 6Department of
Rehabilitation, Sheba Medical Center, Tel-Hashomer, Israel, 7 Faculty of Medicine, Ziv and Padeh Hospitals, Bar-Ilan
University, Safed, Israel
Background and Aims: Post-endoscopic retrograde cholangiopancreatography
(ERCP) pancreatitis (PEP) is one of the major complications of ERCP. Thus, several
non-invasive as well as invasive strategies have been investigated as preventative
therapies for PEP with various efficacy.
Methods: We enrolled any patients who underwent ERCP both at the Shaare Zedek
Medical Center in Jerusalem and EMMS Nazareth hospital. Association between use
of statins and different variables were assessed with univariate tests (chi-squared for
categorical variables). Predictors of incidence of PEP and severity of pancreatitis were
computed using conditional logistic regression, correcting for potential confounding
factors.
Results: 958 subjects were analyzed. Average age was 62.04± 21.18 years (median 68
years). Most of the patients were female (n= 558, 58.2%), Jewish (n= 827, 86.3%), and
inpatients (n= 631, 65.9%). Only few ERCPs were performed emergently (n= 40, 4.2%).
Twenty-Seven patients repeated the exam. Overall incidence of PEP/hyperamylasemia
was 16.8% (n = 161); with a 5.6% (n = 54) incidence of hyperamylasemia and a
11.2% (n = 107) incidence of pancreatitis. Overall, 6 cases of severe pancreatitis were
identified. The logistic regression analysis demonstrated that chronic use of statins is a
protective factor in preventing development of PEP/hyperamylasemia [OR 0.436 [95%CI
0.303–0.627], p < 0.001]; Particularly, the PEP OR was of 0.318 [95%CI 0.169–0.597],
p < 0.001 and the hyperamylasemia OR was of 0.565 [95%CI 0.372–0.859], p = 0.008.
No significant predictor could be found for the risk of developing severe PEP.
Conclusions: Our data support the possibility of exploiting statins as preventive agents
for PEP. However, further studies, mainly RCTs, are warranted in order to replicate our
findings.
Keywords: endoscopic retrograde cholangiopancreatography (ERCP), hyperamylasemia, pancreatitis, statins,
endoscopy
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INTRODUCTION
Endoscopic retrograde cholangiopancreatography (ERCP)
is the current gold-standard for the diagnosis and treatment of
pancreatic and biliary diseases (Canlas and Branch, 2007). It
is normally used for stone disease, ampulla of Vater/papillary
abnormalities, and biliary and pancreatic ductal disorders
(Bor et al., 2015; Ahmed et al., 2017). Nevertheless, ERCP
use has decreased in the last decade due to the widespread
availability of new, non-invasive imaging modalities such
as magnetic resonance cholangiopancreatography (MRCP),
CT and endoscopic US (Ahmed et al., 2017). Post-ERCP
pancreatitis (PEP) may arise as a complication, together with
bleeding, perforation, and cholangitis, with an incidence as
high as 15–20% among high-risk cases (Canlas and Branch,
2007; Chen et al., 2014). PEP consists of new or worsening
abdominal pain, associated with high serum levels of amylase
(at least three times the upper limit of normal) with an
onset of more than 24 h after the procedure (Dumonceau
et al., 2014). The major risk factors for PEP include: female
gender, previous pancreatitis, previous PEP, sphincter of
Oddi dysfunction, intraductal papillary mucinous neoplasm,
difficult cannulation, endoscopic sphincterotomy (EST), precut
sphincterotomy, and main pancreatic duct injection (Ding
et al., 2015; Wang, 2017). As such, prevention modalities
for PEP including patient selection, risk-stratification and/or
prophylactic pancreatic stent placement, are of fundamental
importance (Tarnasky et al., 1998; Wong and Tsai, 2014).
Concerning pharmaco-prevention modalities, to date, non-
steroidal anti-inflammatory drugs (NSAIDs) are the only
medications to be effective in PEP prevention (Cote and
Elmunzer, 2016; Chandrasekhara et al., 2017). Furthermore,
evidence is emerging that rectal administration of NSAIDs
such as indomethacin or diclofenac just before or after ERCP
might reduce the risk and severity of post-procedure pancreatitis
(Dumonceau et al., 2014; Qian et al., 2017). According to the
updated European Society of Gastrointestinal Endoscopy (ESGE)
guidelines for PEP prevention, there is no evidence that drugs
such as corticosteroids, antioxidants, heparin, sphincter of Oddi
pressure reducers, and/or anti-inflammatory drugs (other than
indomethacin and diclofenac) can effectively reduce the risk of
PEP (Dumonceau et al., 2014).
Statins, also known as 3-Hydroxy-3-methylglutaryl-coenzyme
A (HMG-CoA) reductase inhibitors, are commonly used for
lowering blood lipid levels and reducing cardiovascular
risk (Schachter, 2005). Several studies have reported statins
as a cause of acute pancreatitis (Badalov et al., 2007),
yet, many others have shown their efficacy in preventing
it (de-Madaria, 2017). Interestingly, preliminary results
show that chronic statin administration appears to have a
protective effect on the development of PEP (Martinez-Moneo
et al., 2017), yet there are very few studies to assess such
findings. The aim of our study was thus, to fill this gap in
knowledge.
MATERIALS AND METHODS
Ethics Statement
The current study received ethical approval from the hospital
ethical committee and was conducted according to the Helsinki
guidelines. The data was coded to preserve the anonymity of
the patients. Informed consent was waived because of the non-
interventional study design.
Patients Selection
All patients who underwent for ERCP at either the Shaare Zedek
Medical Center in Jerusalem or EMMS Nazareth hospital (Israel)
within the study period of 2013–2015 were considered potentially
eligible and, as such, were enrolled in the study. All patients
underwent to ERCP due to common bile duct (CBD) disorders
and none of them had pancreatic duct or sphincter of Oddi
manometry studies.
PEP was defined as onset of abdominal pain more than 24 h
after the procedure, lasting more than 4 h, with high serum
levels of amylase at least three times the upper limit of normal
and patient admission required. Hyperamylasemia was defined
as an increase of serum levels of amylase above the upper
limit of normal range (normal value 0-90 U/L), associated with
abdominal pain of a duration of less than 4 h. Severity of
pancreatitis was assessed using both revised Atlanta criteria and
APACHE II scores (Larvin and McMahon, 1989; Banks et al.,
2013).
Consumers of statins were defined as patients taking statins
for a period of at least 6 months before the ERCP procedure.
Patients were treated with 20–40mg/die of Simvastatin. Ethnicity
was classified as Jew and non-Jew based on surname analysis.
ERCP procedure was also classified as in an inpatient and
outpatient procedure.
Statistical Analyses
Data was retrieved from medical charts, extracted and entered in
an ad hoc pre-designed spreadsheet. All data was reviewed by an
expert gastroenterologist. Before starting any statistical analysis,
data was visually inspected and checked for outliers. Normality
of data distribution was checked with the Kolmogorov-Smirnov
test. Continuous variables were computed as mean ± standard
deviation andmedian, whilst categorical variables were expressed
as percentages. The association between the use of statins and
different variables was assessed with univariate tests (chi-squared
for categorical variables). Predictors of incidence of PEP and
severity of pancreatitis were computed using conditional logistic
regression, correcting for potential confounding factors. All
statistical analyses were carried out with a commercial software,
Statistical Package for Social Science (SPSS version 24.0, IBM,
Chicago, IL, USA). Figures with p-value less than 0.05 were
considered statistically significant.
RESULTS
Of an initial list of 987 patients, after removing duplicates, 958
subjects (97.1% of the original sample) were analyzed. Average
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age was 62.04 ± 21.18 years (median 68 years). Most of the
patients were female (n = 558, 58.2%), Jewish (n = 827, 86.3%),
and inpatients (n= 631, 65.9%). Only few ERCPs were performed
emergently (n = 40, 4.2%). Twenty-Seven patients repeated the
exam (mean age 65.67 ± 19.08, median 70): most of them were
Jewish (n = 22, 81.5%), female (n = 18, 66.7%), outpatients
(n= 14, 51.9%), and consumers of statins (n= 15, 55.6%).
Overall incidence of PEP/hyperamylasemia was 16.8%
(n = 161): more specifically, incidence of hyperamylasemia
and of pancreatitis was 5.6% (n = 54), and 11.2% (n = 107),
respectively. Overall, 6 cases of severe pancreatitis were
identified. More details are shown in Table 1.
In the univariate analysis, while ethnicity (Jewish) (p= 0.014)
and incidence of pancreatitis/hyperamylasemia (p < 0.001)
were highly significant among the statins treated group, age
was borderline significant (Table 2). Specifically, statistical
significance was achieved both for PEP (8.4 vs. 2.6%, p <
0.001) and hyperamylasemia (14.1 vs. 8.1%, p = 0.003), for
non-consumers and consumers of statins, respectively. The
logistic regression analysis (Table 3), after correcting for all
potential confounding factors, demonstrated that chronic use
of statins is a protective factor in preventing development
of PEP/hyperamylasemia (OR 0.436 [95%CI 0.303–0.627],
p < 0.001); Particularly, the PEP OR was of 0.318 [95%CI 0.169–
0.597], p < 0.001 and the hyperamylasemia OR was of 0.565
[95%CI 0.372–0.859], p = 0.0008. No significant predictor could
be found for the risk of developing severe PEP.
DISCUSSION
In the current study, chronic use of statins (>6 months) was
found to be a protective factor against the development of PEP,
however, it did not significantly affect the severity of pancreatitis.
TABLE 1 | Characteristics of the study population.
Variable Value
Age (mean; median) 62.04 ± 21.18; 68
GENDER (n; %)
Male 400 (41.8%)
Female 558 (58.2%)
ETHNICITY (n; %)
Non-Jew 131 (13.7%)
Jew 827 (86.3%)
Inpatient (n; %) 631 (65.9%)
Outpatient (n; %) 327 (34.1%)
ERCP performed in emergency (n; %) 40 (4.2%)
Repeated ERCP vs. first-time ERCP 27 (2.8%)
USE OF STATINS (n; %)
No statin consumption 497 (51.9%)
Statin consumption 461 (48.1%)
Incidence of post-ERCP pancreatitis/hyperamylasemia (n; %) 161 (16.8%)
Hyperamylasemia 107 (11.2%)
PEP 54 (5.6%)
Severe pancreatitis 6 (0.6%)
PEP/hyperamylasemia is a major complication of the ERCP
procedure (Szary and Al-Kawas, 2013). Therefore, many efforts
have been made in order to decrease the rates of such
complications (Elmunzer et al., 2008; Zheng et al., 2008).
Prophylactic pancreatic stent placement (PSP) seems able to
prevent PEP (risk ratio or RR = 0.28 [95%CI 0.18–0.42]; Hu
et al., 2016; Vadalà di Prampero et al., 2016). Another study has
found that PSP can significantly decrease the risk of PEP in high
risk patients (OR = 0.44, [95%CI 0.24–0.81]) and almost always
prevents severe cases (Andriulli et al., 2007).
Concerning the prophylactic administration of drugs,
NSAIDs such as indomethacin and diclofenac represent two
valid strategies, as a recent meta-analysis of 17 trials, pooling
4,741 patients, has shown a significantly decreased RR of
PEP (RR = 0.60 [95%CI 0.46–0.78]; Patai et al., 2017). Bolus-
administered somatostatin has shown similar effects (RR = 0.63
[95%CI 0.40–0.98]; Hu et al., 2016). Inconsistent results were
reported regarding the use of corticosteroids as a preventive
therapy for PEP. One study has found that the incidence of PEP
in the corticosteroid treated group is around 4.6%, whereas in the
control group it was 7.4–9.1% (Weiner et al., 1995). Nevertheless,
in other studies, corticosteroids failed to reduce the risk of PEP
(Bai et al., 2008; Zheng et al., 2008).
Lee et al. (2017) carried out a historical cohort study recruiting
adult patients with acute pancreatitis, matching patients on
(n= 110) and off (n= 210) statins based on a propensity score in
order to simulate a randomized controlled trial. Authors found
that patients on statins were less likely to develop multisystem
organ failure, severe acute pancreatitis and necrosis. Similarly,
a retrospective cohort study based on data from an integrated
healthcare system in southern California performed by Wu
et al. (2015) found that simvastatin use reduced significantly the
emergence of acute pancreatitis (crude incidence rate ratio or
TABLE 2 | Univariate analysis showing comparison between consumers and
non-consumers of statins.
Variable No use of
statins
(n = 497)
Use of
statins
(n = 459)
Statistical
significance
Age 60.35 ±
22.30
63.81 ±
19.77
0.051
Gender 1.000
Male 207 (41.6%) 192 (41.8%)
Female 290 (58.4%) 267 (58.2%)
Ethnicity 0.014
Non-Jew 55 (11.1%) 76 (16.6%)
Jew 442 (88.9%) 383 (83.4%)
Impatient vs. outpatient 327 (65.8%) 303 (66.0%) 0.946
Emergency 18 (3.6%) 22 (4.8%) 0.420
Repeated ERCP vs.
first-time ERCP
12 (2.4%) 15 (3.3%) 0.426
Pancreatitis/hyperamylasemia 112 (22.5%) 49 (10.7%) <0.001
Pancreatitis 42 (8.4%) 12 (2.6%) <0.001
Hyperamylasemia 70 (14.1%) 37 (8.1%) 0.003
Severe pancreatitis 5 (1.0%) 1 (0.2%) 0.220
Bold values indicates statistically significant.
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TABLE 3 | Predictors of developing post-ERCP pancreatitis and/or hyperamylasemia at the logistic regression.
Source Value Standard
error
Wald
Chi-Square
Pr >
Chi²
Wald lower
bound (95%)
Wald upper
bound (95%)
Odds
ratio
Odds ratio
lower bound
(95%)
Odds ratio
upper bound
(95%)
PEP/HYPERAMYLASEMIA
Intercept −0.907 0.297 9.297 0.002 −1.489 −0.324
Age −0.004 0.004 1.221 0.269 −0.012 0.003 0.996 0.988 1.003
Origin (non-Jew vs. Jew) −0.392 0.290 1.823 0.177 −0.961 0.177 0.676 0.383 1.194
Gender (male vs. female) 0.023 0.179 0.016 0.899 −0.328 0.373 1.023 0.720 1.453
Use of statins −0.830 0.186 20.015 <0.001 −1.194 −0.466 0.436 0.303 0.627
Inpatient vs. outpatient 0.008 0.188 0.002 0.966 −0.361 0.377 1.008 0.697 1.458
Emergency −0.081 0.452 0.032 0.858 −0.966 0.805 0.922 0.380 2.236
Repeated ERCP vs.
first-time ERCP
−2.379 1.452 2.684 0.101 −5.225 0.467 0.093 0.005 1.595
PEP
Intercept −2.028 0.454 19.922 <0.001 −2.918 −1.137
Age −0.007 0.006 1.181 0.277 −0.019 0.005 0.993 0.982 1.005
Origin (non-Jew vs. Jew) −0.531 0.498 1.135 0.287 −1.507 0.446 0.588 0.221 1.561
Gender (male vs. female) 0.050 0.281 0.032 0.859 −0.500 0.600 1.051 0.606 1.822
Use of statins −1.147 0.322 12.658 <0.001 −1.779 −0.515 0.318 0.169 0.597
Inpatient vs. outpatient 0.209 0.305 0.470 0.493 −0.389 0.807 1.233 0.678 2.241
Emergency 0.012 0.683 0.000 0.986 −1.326 1.350 1.012 0.266 3.858
Repeated ERCP vs.
first-time ERCP
−1.087 1.445 0.566 0.452 −3.920 1.745 0.337 0.020 5.726
HYPERAMYLASEMIA
Intercept −1.530 0.350 19.140 <0.0001 −2.215 −0.844
Age −0.003 0.005 0.288 0.592 −0.012 0.007 0.997 0.988 1.007
Origin (non-Jew vs. Jew) −0.240 0.329 0.531 0.466 −0.884 0.405 0.787 0.413 1.499
Gender (male vs. female) 0.006 0.209 0.001 0.975 −0.404 0.417 1.007 0.668 1.517
Use of statins −0.571 0.214 7.145 0.008 −0.990 −0.152 0.565 0.372 0.859
Inpatient vs. outpatient −0.102 0.218 0.221 0.638 −0.529 0.324 0.903 0.589 1.383
Emergency 0.004 0.523 0.000 0.994 −1.021 1.029 1.004 0.360 2.799
Repeated ERCP vs.
first-time ERCP
−1.930 1.445 1.785 0.182 −4.762 0.902 0.145 0.009 2.464
SEVERE PANCREATITIS
Intercept −3.268 1.673 3.816 0.051 −6.546 0.011
Age 0.013 0.019 0.472 0.492 −0.025 0.051 1.013 0.976 1.053
Origin (non-Jew vs. Jew) −0.462 1.691 0.075 0.784 −3.777 2.852 0.630 0.023 17.317
Gender (male vs. female) 0.541 0.787 0.472 0.492 −1.001 2.083 1.717 0.367 8.025
Use of statins −0.172 0.967 0.032 0.859 −2.069 1.724 0.842 0.126 5.606
Inpatient vs. outpatient 0.802 0.958 0.700 0.403 −1.076 2.679 2.229 0.341 14.571
Emergency 0.201 2.058 0.010 0.922 −3.833 4.235 1.223 0.022 69.077
Bold values indicates Statistically significant.
RR = 0.626 [95%CI 0.588–0.668], adjusted RR = 0.29 [95%CI
0.27–0.31]). On the other hand, Kuoppala et al. (2015) performed
a registry-based case-control study based on 4,376 patients
hospitalized for acute pancreatitis age- and sex-matched with
19,859 randomly selected controls from the adult population
of Finland, with 19% cases and 13% controls having been
exposed to statins. Authors found that statin use was associated
with an increased incidence rate of acute pancreatitis (OR 1.25
[95%CI 1.13–1.39]), especially during the first year of use. This
was demonstrated both among current (OR of 1.37 [95%CI
0.94–2.00] for at most 3 months of use and OR of 1.32 [95%CI
1.07–1.63] for 4–12 months of use) and former users (OR 1.64
[95%CI 1.33–2.03]). Shiu et al. (2015) enrolled 31 patients on
statins matched with 63 controls and found that statins had no
beneficial effects on the clinical outcomes of patients with a first
onset acute pancreatitis, while having a positive effect on the
computed tomography severity index.
To the best of our knowledge, this is one the first studies
to prove that chronic statin use reduces the risk of emergence
of PEP. The only group to perform a similar investigation is
of de Madaria et al. (Martinez-Moneo et al., 2017). Authors
recruited a sample of 708 patients (median age of 70 years, 53.5%
men, 29.5% on statins), and computed an incidence of PEP of
1.9% and of 5.8% among the consumers and non-consumers of
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statins, respectively. In the multivariate analysis, lack of statin
consumption was shown to be an independent risk factor for the
development of PEP (OR 3.56 [95%CI 1.19–10.68], p-0.023). A
potential plausible mechanism by which statins might prevent
PEP is their reported anti-inflammatory effects (Blake and
Ridker, 2000). Indeed, statins can modulate the synthesis of
isoprenoids thus affecting the pathways involving endothelial
nitric oxide synthase (Endres et al., 1998). Additionally, statins
were found to have immunomodulatory effects on T-cells,
inducing the secretion of anti-inflammatory cytokines such
as IL-10 and transforming growth factor (TGF)-beta (Youssef
et al., 2002). Furthermore, several studies have shown the
capacity of statins to reduce CRP levels in patients with
acute coronary disease and type II diabetes, despite lack of
changes in cholesterol levels (Kluft et al., 1999; Strandberg
et al., 1999). It was also found that adherence to statins is
associated with lower risk of developing rheumatoid arthritis
(Chodick et al., 2010). Therefore, the reduced risk of PEP
found in our study might be attributed to the heterogeneous
immunomodulatory effects of statins as found in the
previous studies.
However, some drawbacks affect our investigation, the
major limitation being the study design i.e., a retrospective
database-based study as opposed to a randomized
controlled trial (RCT) and missing data concerning levels of
triglycerides.
In conclusion, different approaches with varying
efficacies may be used in order to prevent the emergence
of PEP/hyperamylasemia. Our study seems to suggest the
possibility of exploiting statins as pharmacopreventative agents.
However, despite the strengths of the study, prospective
randomized trials are required to confirm our findings, also
using different ethnicities.
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